SwedenSweden

SOBI swimming

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several external factors had a serious impact on financial performance, emphasising the strong Swedish crown in relation to other currencies and govern­mental health care budget cuts in several European countries. “Conditions on the Euro­pean pharmaceutical market are expected to remain unchanged in 2011, with limited growth,” said SOBI CEO Kenneth Rooth. With this outlook in mind, the firm’s management has applied the brakes: reductions – particularly in personnel – are planned in order to cut operating costs by SEK100m annually. Around 70 staff members will be affected, predominantly in preclinical development, CMC (Chemistry, Manufacturing and Controls) and within the company’s Manufacturing and Quality Control/Quality Assurance in Stockholm. “We have a number of product launches in progress and several late-stage development projects with great market potential. These projects require major resources,” said Rooth. An additional guaranteed issue of common shares valued at around SEK600m should lower SOBI’s debts further. The final terms of the rights issue, including subscription price and number of shares to be issued, have yet to be determined.

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

SwedenSweden

14.09.2010

Stockholm – A recent study from the Karolinska Institute reveals how two types of cellular changes interact in the development of cancer, and the results could improve the chances of early discovery of sarcomas. Pancreatic cancer...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/sobi-swimming.html

Product of the week

Products

Events

All Events

Current issue

All issues